Quality Medical Innovations Pty Ltd v Keogh

Link copied
Case Copied 49 min read

FEDERAL COURT OF AUSTRALIA

Quality Medical Innovations Pty Ltd v Keogh [2021] FCA 154  

File number: NSD 1171 of 2020
Judgment of: MARKOVIC J
Date of judgment: 2 March 2021
Catchwords: CORPORATIONS – directors’ duties – where first defendant is a director of the first plaintiff and second defendant – where second defendant produces and sells products in a similar market to the first plaintiff – application for injunctive relief under s 1324 of the Corporations Act 2001 (Cth) (Corporations Act) – alleged contraventions of ss 181-183 of the Corporations Act – whether the evidence establishes a sufficiently seriously arguable case of those contraventions – whether balance of convenience favours the grant of relief sought – application dismissed
Legislation: Corporations Act 2001 (Cth) ss 181, 182, 183, 1324
Cases cited:

Armstrong World Industries (Australia) Pty Limited v Parma (2014) 101 ACSR 150; [2014] FCA 743

Australian Careers Institute Pty Ltd v Australian Institute of Fitness Pty Ltd (2016) 340 ALR 580; [2016] NSWCA 347

Australian Securities and Investments Commission v Adler (2002) 168 FLR 253

Australian Securities and Investments Commission v Mauer-Swisse Securities Limited (2002) 42 ACSR 605 at 613-614; [2002] NSWSC 741

Beecham Group Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618

Fitzpatrick v Cheal (2012) 264 FLR 313; [2012] NSWSC 261

In the matter of Ikon Group Limited (2015) 107 ACSR 146; [2015] NSWSC 980

Links Golf Tasmania Pty Ltd v Sattler (2012) 213 FCR 1

Parker v Tucker (2010) 77 ACSR 525; [2010] FCA 263

Samsung Electronics Co Ltd v Apple Inc (2011) 217 FCR 238

Division: General Division
Registry: New South Wales
National Practice Area: Commercial and Corporations
Sub-area: Corporations and Corporate Insolvency
Number of paragraphs: 96
Date of hearing: 16 February 2021
Counsel for the Plaintiffs: Mr M Maconachie
Solicitor for the Plaintiffs: Donovan Oates Hannaford
Counsel for the Defendants: Mr J Conde
Solicitor for the Defendants: Thynne + Macartney

ORDERS

NSD 1171 of 2020
BETWEEN:

QUALITY MEDICAL INNOVATIONS PTY LTD ACN 101 586 476

First Plaintiff

MR KIM LEONARD GAUL

Second Plaintiff

AND:

MR MICHAEL PHILLIP KEOGH

First Defendant

MAJAC MEDICAL PRODUCTS PTY LIMITED ACN 086 942 421

Second Defendant

ORDER MADE BY:

MARKOVIC J

DATE OF ORDER:

2 MARCH 2021

THE COURT ORDERS THAT:

1.Paragraphs 2 to 6 of the plaintiffs’ interlocutory application filed on 4 December 2020 be dismissed.

2.Each party pay their own costs of this application.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

MARKOVIC J:

  1. On 27 October 2020, Kim Leonard Gaul as plaintiff commenced this proceeding against Quality Medical Innovations Pty Limited (QMI), Michael Phillip Keogh and Majac Medical Products Pty Limited (Majac) as first, second and third defendants respectively.  Dr Gaul and Mr Keogh are both directors of and equal shareholders in QMI.  Mr Keogh is the sole director of and shareholder in Majac.  

  2. At the time of commencement of the proceeding…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Quality Medical Innovations Pty Ltd v Keogh and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2021] FCA 154
Decision Date

CaseChat Overview and Summary

Quality Medical Innovations Pty Ltd and Dr Gaul applied to the Federal Court for injunctive relief against Mr Keogh and Majac. The plaintiffs sought relief to restrain the defendants from certain activities in the infection control products market, as well as orders for the escrow of proceeds from sales of certain products. The defendants opposed the application and Mr Keogh proffered an undertaking to the Court to the effect that the defendants would be restrained from making representations in trade or commerce about any products of QMI or any brand or trademark associated with QMI. The Court had to determine whether the plaintiffs had established a sufficiently seriously arguable case of contraventions of the directors' duties under the Corporations Act, and whether the balance of convenience favoured the grant of the relief sought. The Court found that while there was some evidence of the serious nature of the plaintiffs' case, it was not enough to establish that the case was seriously arguable. Further, the Court found that the balance of convenience did not favour the grant of relief as the defendants would suffer prejudice if the relief was granted. The Court dismissed the balance of the relief sought by the plaintiffs and ordered that each party pay their own costs of the application.

Orders

Orders of the court

1. Paragraphs 2 to 6 of the plaintiffs’ interlocutory application filed on 4 December 2020 be dismissed.

2. Each party pay their own costs of this application.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Mr Keogh and Majac oppose the balance of the relief sought by Dr Gaul and QMI in paras 2 and 3 of the IP. EVIDENCE Dr Gaul and QMI relied on three affidavits sworn by Dr Gaul on 23 October 2020, 4 December 2020 and 11 February 2021. Mr Keogh and Majac relied on two affidavits affirmed by Jessica Louise Carroll, a solicitor in the employ of Thynne + Macartney, their solicitors, on 1 February 2021 and 15 February 2021. I set out below a summary of the evidence relevant to the application now before me.QMI is established In 2000, Dr Gaul, Mr Keogh and Linley Lochead formed a partnership to produce and market infection control products for the healthcare industry. They called the partnership business Quality Medical Innovations and referred to it as QMI. The partnership business was conducted on the basis that Dr Gaul, Mr Keogh and Ms Lochead were equal partners. As far as Dr Gaul can recall, there was no formal partnership agreement. At about the same time as the formation of the partnership, there was also an agreement between Dr Gaul, Mr Keogh and Ms Lochead that Majac sell QMI products. Majac subsequently became the sole distributor of those products. On 5 August 2002 QMI was registered as a company. Upon its registration, Dr Gaul, Mr Keogh and Ms Lochead were appointed directors of, and were equal shareholders in, the company, each holding ten shares. QMI continued to sell and distribute its products solely through Majac. On 30 October 2003 Ms Lochead resigned as a director of QMI and in March 2014 she sold her shares in QMI to Dr Gaul. Subsequently Dr Gaul transferred five of the shares he acquired from Ms Lochead to Mr Keogh at the same price that he had paid per share to Ms Lochead. Trade marks used by QMI QMI uses trade marks, which are registered in the names of Dr Gaul and Mr Keogh, for its products. According to Dr Gaul the following trade marks (QMI Trade Marks), in each case registered in his and Mr Keogh’s names, are used by QMI: Dr Gaul had originally intended for the Clinidet trade mark to be registered in the joint names of all of the partners. However, he recalls that at the time of its registration a conversation to the following effect took place:Ms Lochead:I don't want to have any trademarks in my name. I think it would compromise my consulting work because of the potential conflict of interest.Dr Gaul:That is understandable. It doesn't matter who holds the trademarks, since they belong to the partnership anyway.Mr Keogh:I agree. Kim and I can hold the trademarks in our names on behalf of the partnership. Dr Gaul has always regarded all of the QMI Trade Marks as the property of QMI. Despite that, on 20 September 2006, Dr Gaul, Mr Keogh and QMI entered into a trade mark licence (TM Licence). While Dr Gaul cannot now remember precisely why that was so, he recalls that it related to ensuring that QMI had a legal right to the use of some of the QMI Trade Marks. At the time there was a dispute relating to those trade marks and Dr Gaul opines that it may be that dispute that led to the entry into of the TM Licence.

Decision

Reasons for decision

Fourthly, there is some evidence of the prejudice which Mr Keogh and Majac would suffer should the relief sought be granted such as loss of income (and its effect) and the potential for redundancies. CONCLUSION For those reasons I decline to grant the relief sought in paras 2 and 3 of the IP. As the relief sought in para 1 of the IP was dealt with by consent on another occasion, the appropriate order is to dismiss the balance of the IP. That leaves the question of costs. Subject to one matter, QMI and Dr Gaul have been unsuccessful in their application. That one matter concerns the Undertaking. While that was proffered by Mr Keogh without the need for me to resolve the issue, that occurred in the course of the hearing of the IP and after QMI and Dr Gaul had made their submissions and developed their case, much of which focussed on the relief sought in para 2(a) which is the subject of the Undertaking. On one view the Undertaking represents some success for QMI and Dr Gaul on their IP. In those circumstances, the appropriate order is that each party should pay their own costs of this application. I will make orders accordingly.

Ratio Decidendi

Legal Principle Established

At the time of commencement of the proceeding Dr Gaul sought relief under s 232 and s 233 of the Corporations Act 2001 (Cth) (Corporations Act) and orders requiring QMI to commence proceedings against Mr Keogh and Majac for, among other things, alleged breaches by Mr Keogh of his director’s duties and passing off. On 4 December 2020, Dr Gaul filed an interlocutory process (IP) seeking leave to commence proceedings in the name of QMI against Mr Keogh and Majac in respect of causes of action pleaded in a draft statement of claim (which has been subsequently filed) and for interim injunctive relief pursuant to s 1324 of the Corporations Act. On 14 December 2020, orders were made by consent including an order granting Dr Gaul leave to join QMI as a plaintiff to the proceeding and otherwise dismissing Dr Gaul’s application for leave to commence a proceeding in the name of QMI as sought in para 1 of the IP. As a result, the parties to this proceeding now comprise QMI and Dr Gaul as first and second plaintiffs respectively and Mr Keogh and Majac as first and second defendants respectively. QMI and Dr Gaul press their application for interim injunctive relief included at paras 2 and 3 of the IP. They seek the following orders:2.An order that [Mr Keogh and Majac], by themselves, their employees, or agents, be restrained until further order from:(a)making representations in trade or commerce about or relating to any products of [QMI], or any brand or trademark associated with [QMI];(b)offering for sale, under any trading name, brand or trademark, any product created or derived from chemical formulae being the property of [QMI];(c)offering for sale, under any trading name, brand or trademark, any product created or derived from formulae for the products offered for sale by [QMI] under any of the trademarks set out in the schedule attached hereto in the column headed "QMI Trademark";(d)offering for sale any product under the trademarks or brands set out in the schedule attached hereto in the column headed "Majac mark".3. In the alternative to prayer 2, an order that until further order:(a)[Majac] pay all proceeds from the sale of any product sold under any of the brands set out in the schedule attached hereto in the column headed "Majac mark" into a bank account dedicated for that purpose (Escrow Account);(b)[Majac] be restrained from withdrawing any funds from the Escrow Account save for any account-keeping or other administrative fees relating to the maintenance of the Escrow Account;(c)[Majac] is to provide to the plaintiff a monthly statement for the Escrow Account;(d)[Majac] is to facilitate inspection of its books and records by qualified professionals engaged on behalf of the plaintiff for the purpose of confirming [Majac’s] compliance with these orders. In the course of the hearing of QMI and Dr Gaul’s application for the relief set out in the preceding paragraph, Mr Keogh proffered an undertaking (Undertaking) to the Court until determination or settlement of the proceeding or further order in the terms of para 2(a) of the IP which has been noted. The Undertaking is a complete answer to the claim for relief in para 2(a) of the IP.